Skip to main content

Table 4 MDSCs in HSCT

From: Myeloid-derived suppressor cells in hematological malignancies: friends or foes

HSCT or models MDSC subgroups/phenotype definition Clinical finding Mechanism/intervention Year/reference
Unrelated HSCT, N = 51 M-MDSCs
HLA-DRlow/−CD14+
The frequency of M-MDSCs was significantly increased after allo-HSCT, especially in patients with acute graft-versus-host disease Blocking the IDO activity of M-MDSCs restore immune tolerance 2013 [20]
Unrelated-HSCT G-PB, N = 60 M-MDSCs
Linlow/negHLA-DRCD11b+CD33+CD14+
MDSCs in graft as only independent risk factors reducing aGvHD, MDSCs did not impact the relapse rate or the transplant-related mortality rate Suppress alloreactive T cells 2014 [63]
Haplo-HSCT
G-BM and PB, N = 62
M-MDSCs
Lin-HLA-DR−/lowCD33 + CD11b + CD14 + CD15dimCD16-
eMDSCs
LinHLA-DR−/lowCD33+CD11b−/lowCD14CD15CD16
MDSCs in graft as independent factors that reduced the occurrence of grade II-IV aGvHD and extensive cGvHD, Delayed M-MDSC reconstitution was associated with aGvHD onset. MDSCs did not impact the relapse rate or the transplant-related mortality rate Suppress alloreactive T cells 2015 [64]
MSD-HSCT
G-PB or G-BM, N = 101
MDSCs
Linlow/negHLA-DRCD33+CD11b+
MDSCs in G-BM rather than G-PB was correlated with better GRFS and less GVHD Immunosuppressive activity of MDSCs was similar in the G-BM and G-PB grafts 2017 [65]
Allo
G-BM and PB, N = 100
eMDSCs
HLA-DR−/lowCD33 + CD16-
MDSCs in G-BM and G-PB as independent factors that reduced the occurrence of grade II-IV aGvHD.
MDSCs did not impact the relapse rate or the transplant-related mortality rate
TGF-β signal
Th2 differentiation
Treg induction
2019 [66]